INTRODUCTION: Worldwide, there is an increasing thrust to develop better screening methods for preeclampsia. But in the Philippines, there is limited research regarding approach to screening for development of preeclampsia. This retrospective study aimed to identify significant clinical risk factors associated with preeclampsia and develop a risk scoring index. METHODS: A retrospective cohort study of women with live births at a tertiary hospital, St. Luke’s Medical Center from January 2015 to April 2016 was conducted. Several variables associated with Preeclampsia were considered. Outcome measure was development of preeclampsia. A risk scoring index was developed from the results of the logistic regression analysis. Computed scores were plotted in a receiver operating characteristic curve and cut-off values were determined. RESULTS: The overall prevalence of preeclampsia was 4.5%. Among the variables evaluated, presence of chronic hypertension (OR 4.179, 95% CI 7.572-563.181) and respiratory tract infection (OR 3.128, 95% CI 4.196-124.263) showed the strongest significant association with development of Preeclampsia. The odds of developing preeclampsia were also increased in patients who had gestational diabetes mellitus (OR 1.222, 95% CI 1.559-7.389), urinary tract infection (OR 2.455, 95% CI 5.723-23.678), and vaginal infection (OR 1.577, 95% CI 2.126-11.020). The formulated preeclampsia risk scoring index was 5.75, specificity of 91.8%, sensitivity of 74.5%, positive likelihood ratio of 9.2. CONCLUSION: Maternal age, and presence of chronic hypertension, gestational diabetes mellitus, and maternal infection significantly affect development of preeclampsia among women studied. Women are more likely to develop preeclampsia 9 times more with a risk score of greater than or equal to 5.75.
Juvenile-onset recurrent respiratory papillomatosis (JORRP) is a rare disease, usually acquired by vertical transmission upon vaginal delivery. Human Papilloma Virus (HPV) is the etiologic agent and the most common types involved are 6 and 11 that are the same types associated with anogenital condylomas. It is associated with low mortality but with significant morbidity. Pregnancy was related with accelerated papilloma growth in RRP, while RRP may have an effect on the outcome of pregnancy due to chronic maternal hypoxemia. We present a case of Juvenile onset recurrent respiratory papilloma in pregnancy seen starting 7 weeks age of gestation. The effect of pregnancy on JORRP, its effect on pregnancy, and the latest modalities in treatment including the role of HPV vaccination are discussed in the article with the review of literature.
Juvenile-onset recurrent respiratory papillomatosis (JORRP) is a rare disease, usually acquired by vertical transmission upon vaginal delivery. Human Papilloma Virus (HPV) is the etiologic agent and the most common types involved are 6 and 11 that are the same types associated with anogenital condylomas. It is associated with low mortality but with significant morbidity. Pregnancy was related with accelerated papilloma growth in RRP, while RRP may have an effect on the outcome of pregnancy due to chronic maternal hypoxemia. We present a case of Juvenile onset recurrent respiratory papilloma in pregnancy seen starting 7 weeks age of gestation. The effect of pregnancy on JORRP, its effect on pregnancy, and the latest modalities in treatment including the role of HPV vaccination are discussed in the article with the review of literature.Keywords: recurrent respiratory papillomatosis, pregnancy, human papilloma virus Citation: Malabanan LM, Zamora BB. Juvenile recurrent respiratory papillomatosis in pregnancy: a case report.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.